virion

By Targets:	Antibiotic (1) Enterovirus (1) Fungal (1) HBV (1) Histone Methyltransferase (1) HIV (2) Isotope-Labeled Compounds (1) Parasite (1)
By Research Areas:	Cancer (1) Infection (3) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-104074

Pocapavir 3 Publications Verification SCH-48973; V-073	Enterovirus	Infection
Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .

HY-101938

Sinefungin 1 Publications Verification Adenosyl-Ornithine; A-9145; Antibiotic 32232RP	Histone Methyltransferase Fungal Antibiotic Parasite	Infection Inflammation/Immunology
Sinefungin is a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication . Sinefungin, a SET7/9 inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation .

HY-148151

(-)-5′-Noraristeromycin	HBV	Cancer
(-)-5′-Noraristeromycin is an antiviral agent. (-)-5′-Noraristeromycin also is an enantiomer of 5'-noraristeromycin and can inhibit intracellular HBV replication and virion production. (-)-5′-Noraristeromycin can be used for the research of cancer .

HY-P5363

PAP 248–286 Prostatic Acid Phosphatase(248-286)	HIV	Others
PAP 248–286 is a biological active peptide. (Prostatic Acid Phosphatase (248-286), PAP (248-286) peptide is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells.)

HY-104074S

Pocapavir-d3 SCH-48973-d₃; V-073-d₃	Isotope-Labeled Compounds	Others
Pocapavir-d₃ (SCH-48973-d₃; V-073-d₃)is the deuterium labeledPocapavir(HY-104074) . Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .

HY-120157

Vif-ElonginC interaction inhibitor 1	HIV	Infection
Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict HIV-1 in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity .

Cat. No.	Product Name

HY-L027

Antiviral Compound Library	1270 compounds
Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs. MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Antiviral Compound Library

1270 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P5363

PAP 248–286 Prostatic Acid Phosphatase(248-286)	HIV	Others
PAP 248–286 is a biological active peptide. (Prostatic Acid Phosphatase (248-286), PAP (248-286) peptide is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells.)

Species:	Virus (3)
Tag:	His (4) Strep (1) Myc (2)
Source:	HEK293 (1) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72300

	Protein L1/VACWR088, Vaccinia virus (Sf9, His, myc) virion membrane protein M25	Virus	Sf9 insect cells
	Protein L1/VACWR088 is a crucial part of the entry fusion complex (EFC) comprising 11 proteins. It facilitates the entry of the virion core into the host cytoplasm through a two-step process involving lipid mixing and pore formation. All EFC proteins, except OPG095/L1 and OPG053/F9, contribute to the assembly or stability of the complex. Protein L1/VACWR088, Vaccinia virus (Sf9, His, myc) is the recombinant Virus-derived protein L1/VACWR088, expressed by Sf9 insect cells , with N-His, C-Myc labeled tag. The total length of Protein L1/VACWR088, Vaccinia virus (Sf9, His, myc) is 182 a.a., with molecular weight of ~26 kDa.

HY-P72301

	Protein L1/L1R, Vaccinia virus (Sf9, His, myc) 1 Publications Verification virion membrane protein M25	Virus	Sf9 insect cells
	Protein L1/L1R is part of the entry fusion complex (EFC) composed of 11 proteins. This complex facilitates the entry of the virion core into the host cytoplasm through a two-step process: lipid mixing of viral and cellular membranes, followed by pore formation. The assembly or stability of the EFC relies on all proteins except OPG095 and OPG053. Protein L1/L1R, Vaccinia virus (Sf9, His, myc) is the recombinant Virus-derived protein L1/L1R, expressed by Sf9 insect cells , with N-His, C-Myc labeled tag. The total length of Protein L1/L1R, Vaccinia virus (Sf9, His, myc) is 182 a.a., with molecular weight of ~27 kDa.

HY-P701851

	gp15 Protein, Escherichia phage T7 (His, Strep) Internal virion protein gp15; Gene product 15; Gp15	Others	E. coli
	Gp15 protein, part of the inner core during viral capsid formation, aids in ejecting viral DNA into the host cell. It forms a complex with gp16 and binds to both viral DNA and the host inner membrane. Gp15 interacts with gp14 and likely remains associated with gp16, controlling the translocation of DNA into the cell. gp15 Protein, Escherichia phage T7 (His, Strep) is the recombinant gp15 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of gp15 Protein, Escherichia phage T7 (His, Strep) is 746 a.a., .

HY-P75274

	Ebola virus Glycoprotein/GP Protein (AHX24649, HEK293, His) Ebola virus EBOV (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein / GP (virion spike glycoprotein) Protein (His)	Virus	HEK293
	Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (AHX24649, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (AHX24649, HEK293, His) is 650 a.a., with molecular weight of ~54.8 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-104074S

Pocapavir-d3
Pocapavir-d₃ (SCH-48973-d₃; V-073-d₃)is the deuterium labeledPocapavir(HY-104074) . Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.